Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis

被引:22
作者
Lay, Marla
Mariappan, Rajan
Gotlib, Jason
Dietz, Lisa
Sebastian, Siby
Schrijver, Iris
Zehnder, James L.
机构
[1] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Mol Pathol Lab, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Med Hematol, Stanford, CA 94305 USA
[4] Stanford Hosp & Clin, Stanford, CA USA
[5] Lucile Packard Childrens Hosp, Stanford, CA USA
[6] Duke Univ, Med Ctr, Dept Pathol, Durham, NC USA
关键词
D O I
10.2353/jmoldx.2006.050130
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
A point mutation in the JAK2 gene, a member of the tyrosine kinase family, was recently identified and shown to be associated with several myeloproliferative disorders. Several studies identified the same JAK2 point mutation (1849G > T), resulting in the substitution of a valine to phenylalanine at codon 617 (V617F). We developed a simple and sensitive method to detect this mutation via polymerase chain reaction and probe dissociation analysis using the LightCycler platform, and we compared this method to existing restriction fragment-length polymorphism, direct sequencing, and amplification refractory mutation system methods. We found that the LightCycler method offered advantages of speed, reliability, and more straightforward interpretation over the restriction fragment-length polymorphism and sequencing approaches.
引用
收藏
页码:330 / 334
页数:5
相关论文
共 10 条
  • [1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [2] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    James, C
    Ugo, V
    Le Couédic, JP
    Staerk, J
    Delhommeau, F
    Lacout, C
    Garçon, L
    Raslova, H
    Berger, R
    Bennaceur-Griscelli, A
    Villeval, JL
    Constantinescu, SN
    Casadevall, N
    Vainchenker, W
    [J]. NATURE, 2005, 434 (7037) : 1144 - 1148
  • [3] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
    Jones, AV
    Kreil, S
    Zoi, K
    Waghorn, K
    Curtis, C
    Zhang, LY
    Score, J
    Seear, R
    Chase, AJ
    Grand, FH
    White, H
    Zoi, C
    Loukopoulos, D
    Terpos, E
    Vervessou, EC
    Schultheis, B
    Emig, M
    Ernst, T
    Lengfelder, E
    Hehlmann, R
    Hochhaus, A
    Oscier, D
    Silver, RT
    Reiter, A
    Cross, NCP
    [J]. BLOOD, 2005, 106 (06) : 2162 - 2168
  • [4] A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics, R
    Passamonti, F
    Buser, AS
    Teo, S
    Tiedt, R
    Passweg, JR
    Tichelli, A
    Cazzola, M
    Skoda, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790
  • [5] The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
    Levine, RL
    Loriaux, M
    Huntly, BJP
    Loh, ML
    Beran, M
    Stoffregen, E
    Berger, R
    Clark, JJ
    Willis, SG
    Nguyen, KT
    Flores, NJ
    Estey, E
    Gattermann, N
    Armstrong, S
    Look, AT
    Griffin, JD
    Bernard, OA
    Heinrich, MC
    Gilliland, DG
    Druker, B
    Deininger, MWN
    [J]. BLOOD, 2005, 106 (10) : 3377 - 3379
  • [6] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Levine, RL
    Wadleigh, M
    Cools, J
    Ebert, BL
    Wernig, G
    Huntly, BJP
    Boggon, TJ
    Wlodarska, L
    Clark, JJ
    Moore, S
    Adelsperger, J
    Koo, S
    Lee, JC
    Gabriel, S
    Mercher, T
    D'Andrea, A
    Fröhling, S
    Döhner, K
    Marynen, P
    Vandenberghe, P
    Mesa, RA
    Tefferi, A
    Griffin, JD
    Eck, MJ
    Sellers, WR
    Meyerson, M
    Golub, TR
    Lee, SJ
    Gilliland, DG
    [J]. CANCER CELL, 2005, 7 (04) : 387 - 397
  • [7] Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    Tefferi, A
    Sirhan, S
    Lasho, TL
    Schwager, SM
    Li, CY
    Dingli, D
    Wolanskyj, AP
    Steensma, DP
    Mesa, R
    Gilliland, DG
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 166 - 171
  • [8] Tefferi A, 2005, NEW ENGL J MED, V353, P1416
  • [9] The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders:: Status report and immediate implications for disease classification and diagnosis
    Tefferi, A
    Gilliland, DG
    [J]. MAYO CLINIC PROCEEDINGS, 2005, 80 (07) : 947 - 958
  • [10] JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
    Wolanskyj, AP
    Lasho, TL
    Schwager, SM
    McClure, RF
    Wadleigh, M
    Lee, SJ
    Gilliland, DG
    Tefferi, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 208 - 213